Twist Bioscience Corporation Common Stock (TWST) fair value

ACCE thesis

Twist Bioscience makes synthetic DNA, including gene fragments, oligo pools and clonal genes, sold to pharma, biotech and academic labs that need custom sequences for drug discovery, antibody work and synthetic biology. Its moat is process know-how in silicon-based DNA synthesis, which has let it keep gross margins around 52% even as it scales, a rare combination in a sector where most tools businesses struggle to hold margins. Revenue growth of 23.2% is the number to watch, since the thesis rests on operating leverage: the company still runs an operating margin of -30.6%, so each incremental dollar of sales needs to fall through faster than fixed costs grow. The score of 51/100 and the absence from any index tell you the market is not yet paying for that leverage, which is why it deserves a look if you think the margin path is credible. The key debate is whether DNA synthesis demand is growing fast enough, and whether the cash burn implied by a -29.6% return on equity is funded long enough for that margin story to play out.